NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIMBEX PRESERVATIVE FREE (cisatracurium besylate) by AbbVie is end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. First approved in 1995.
Drug data last refreshed 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIMBEX PRESERVATIVE FREE is a nondepolarizing neuromuscular blocking agent (cisatracurium besylate) administered intravenously for muscle relaxation during general anesthesia and perioperative sedation. It works by antagonizing acetylcholine at the neuromuscular junction, blocking neuromuscular transmission; this effect is reversible with acetylcholinesterase inhibitors such as neostigmine. The preservative-free formulation addresses clinical preferences for minimizing additives in injectable anesthetics.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (score: 30/100), signaling potential team downsizing or redeployment within AbbVie's perioperative portfolio.
Mechanism of Action
end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIMBEX offers exposure to hospital-based sales, anesthesia protocol influence, and defensive brand management in a mature market. Career advancement on this product is limited; professionals should expect lateral moves into emerging perioperative assets (e.g., reversal agents, novel induction agents) or broader portfolio roles as generics erode revenue.
Brand Manager (anesthesia)
Worked on NIMBEX PRESERVATIVE FREE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.